Non-mRNA jab targeting common mutations in pancreatic and bowel cancers could lower risk of relapse
An off-the-shelf vaccine has shown promise in preventing the return of pancreatic and colorectal cancer, researchers have revealed.
Cancer vaccines have been the subject of promising research in recent years. The NHS in England has been trialling various jabs in patients through the Cancer Vaccine Launch Pad (CVLP).
Such vaccines train the body’s immune system to recognise cancer cells so any that return after treatments such as surgery can be hunted down and killed, reducing the risk of the disease coming back.
Many cancer vaccines, including some of those based on mRNA technology, are personalised to the patient’s tumours.
